Patents Assigned to Taiho Pharmaceutical Co., LTD
-
Publication number: 20210024530Abstract: Provided are a novel pyrimidine compound that inhibits HER2 activity and exhibits brain penetration properties, or a salt thereof, and a pharmaceutical composition comprising the same. A compound represented by the following formula (I), or a salt thereof: wherein R1 represents a C1-C4 alkyl group optionally having a C1-C4 alkoxy group as a substituent, or a C3-C4 cycloalkyl group; R2 represents a hydrogen atom, a halogen atom, a C1-C6 alkyl group optionally having 1 to 5 C1-C4 alkoxy groups or fluorine atoms each as a substituent(s), or a C1-C6 alkoxy group; R3 represents a hydrogen atom, or a C1-C4 alkyl group optionally having 1 to 5 fluorine atoms as a substituent(s); R4 represents a hydrogen atom or a C1-C4 alkyl group; and R5 represents a phenyl group optionally having 1 to 3 substituents selected from fluorine atoms and chlorine atoms.Type: ApplicationFiled: October 8, 2020Publication date: January 28, 2021Applicant: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Masayuki NAKAMURA, Takahiro ASAI, Satoru IGUCHI, Kei OGUCHI
-
Patent number: 10894048Abstract: The problems to be solved by the present invention are to provide a novel FGFR inhibitor that is potent and highly selective, and to provide an antitumor agent with which side effects such as an elevated blood phosphorus concentration are alleviated while maintaining the antitumor effect of the FGFR inhibitor. The present invention provides an antitumor agent comprising a 3,5-di-substituted benzene alkynyl compound represented by general formula (I) or salt thereof, which is used by administering the 3,5-di-substituted benzene alkynyl compound or salt thereof according to an administration schedule of two or more times/week at an administration interval of at least one day between doses.Type: GrantFiled: February 13, 2019Date of Patent: January 19, 2021Assignee: Taiho Pharmaceutical Co., Ltd.Inventors: Hiroaki Ochiiwa, Hiroshi Hirai
-
Patent number: 10889555Abstract: The present invention provides a novel sulfonamide compound having a ribonucleotide reductase inhibitory activity or a salt thereof, and a pharmaceutical composition containing the same as an active ingredient. A compound represented by Formula (I) [wherein, X1 represents an oxygen atom or the like; X2 represents an oxygen atom; X3 represents —NH—; X4 represents a hydrogen atom or the like; R1 represents —C(R11)(R12)— or the like; R11 and R12 are the same or different and each represents a hydrogen atom or the like; R2 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R3 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R4 represents a hydrogen atom or the like] or a salt thereof.Type: GrantFiled: January 24, 2020Date of Patent: January 12, 2021Assignee: Taiho Pharmaceutical Co., Ltd.Inventors: Seiji Miyahara, Hiroyuki Ueno, Shoki Hara, Yoshio Ogino
-
Publication number: 20200405697Abstract: The present invention provides a method of enhancing an antitumor effect by a compound strongly inhibiting ribonucleotide reductase (RNR) or a salt thereof. A combination formulation involving combined administration of a sulfonamide compound represented by Formula (I) [In the formula, X1 represents an oxygen atom or the like; X2 represents an oxygen atom; X3 represents —NH—; X4 represents a hydrogen atom or the like; R1 represents —C(R11) (R12)— or the like; R11 and R12 are the same or different and each represents a hydrogen atom or the like; R2 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R3 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R4 represents a hydrogen atom or the like] or a salt thereof, having RNR inhibitory activity, and other antitumor agent(s).Type: ApplicationFiled: November 28, 2018Publication date: December 31, 2020Applicant: Taiho Pharmaceutical Co., Ltd.Inventors: Hiroyuki Ueno, Takuya Hoshino
-
Publication number: 20200399235Abstract: The present invention provides a novel sulfonamide compound having a ribonucleotide reductase inhibitory activity or a salt thereof, and a pharmaceutical composition containing the same as an active ingredient. A compound represented by Formula (I) [wherein, X1 represents an oxygen atom or the like; X2 represents an oxygen atom; X3 represents —NH—; X4 represents a hydrogen atom or the like; R1 represents —C(R11)(R12)— or the like; R11 and R12 are the same or different and each represents a hydrogen atom or the like; R2 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R3 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R4 represents a hydrogen atom or the like] or a salt thereof.Type: ApplicationFiled: August 24, 2020Publication date: December 24, 2020Applicant: Taiho Pharmaceutical Co., Ltd.Inventors: Seiji Miyahara, Hiroyuki Ueno, Shoki Hara, Yoshio Ogino
-
Patent number: 10866219Abstract: This invention provides a method that is capable of detecting a trifluridine-related substance and a tipiracil-related substance contained in a sample containing trifluridine or a salt thereof and tipiracil or a salt thereof using the same procedure. The method is for detecting a trifluridine-related substance or a tipiracil-related substance or both, the method comprising the step of subjecting a sample containing trifluridine or a salt thereof and tipiracil or a salt thereof to high-performance liquid chromatography using a mobile phase composed of an organic phase and an aqueous phase.Type: GrantFiled: April 13, 2018Date of Patent: December 15, 2020Assignee: TAIHO PHARMACEUTICAL CO., LTD.Inventor: Yoshinori Tokimitsu
-
Patent number: 10849886Abstract: Provided is a novel method for treating cancer using an HSP90 inhibitor which exhibits a markedly superior antitumor effect and has a reduced side effect. An antitumor agent is characterized in that an azabicyclo compound of the following Formula (1) or a salt thereof is administered in combination with other antitumor agent(s).Type: GrantFiled: April 21, 2017Date of Patent: December 1, 2020Assignee: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Hiromi Muraoka, Akira Kanoh
-
Publication number: 20200361883Abstract: The present disclosure relates to novel crystalline forms of sulfonamide compounds, pharmaceutical compositions containing the crystalline form compounds and methods of preparing and using the same.Type: ApplicationFiled: November 28, 2018Publication date: November 19, 2020Applicant: Taiho Pharmaceutical Co., Ltd.Inventors: Hiroyuki Nakamura, Jing Teng, Nathan Gignac
-
Patent number: 10835536Abstract: The problem to be solved by the present invention is to provide an anticancer agent for treating tumors resistant to other antitumor agents that inhibit FGFR, and a method for treating such tumors. The present invention provides an antitumor agent for administration to a tumor patient resistant to an FGFR inhibitor, the antitumor agent comprising a 3,5-disubstituted benzene alkynyl compound represented by Formula (I) below or a salt thereof. The present invention also provides a therapeutic method using the anticancer agent.Type: GrantFiled: October 2, 2018Date of Patent: November 17, 2020Assignee: Taiho Pharmaceutical Co., Ltd.Inventor: Hiroshi Sootome
-
Patent number: 10816517Abstract: The present invention provides a novel method that is capable of detecting a trifluridine-related substance from a sample containing trifluridine or a salt thereof by high-performance liquid chromatography comprising two steps that are performed under gradient conditions. More specifically, the method is for detecting a trifluridine-related substance, the method comprising the step of subjecting a sample containing trifluridine or a salt thereof to high-performance liquid chromatography using a mobile phase composed of an organic phase and an aqueous phase, wherein the step of high-performance liquid chromatography comprises steps 1 and 2 that satisfy the following requirements: Step 1: the percentage of the organic phase in the entire mobile phase is 1 to 14% by volume; and Step 2: after step 1, elution is performed by applying a gradient of increasing the percentage of the organic phase in the entire mobile phase.Type: GrantFiled: July 20, 2018Date of Patent: October 27, 2020Assignee: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Daisuke Takeda, Akiyo Kojima
-
Patent number: 10807986Abstract: The problem to be solved by the present invention is to provide a novel compound having RET inhibitory activity. The present invention also provides a pharmaceutical preparation that is useful for the prevention and/or treatment of RET-related diseases, particularly cancer, based on RET inhibitory activity. The present invention provides a compound represented by Formula (I): wherein A, R2, and X are as defined in the specification; or a salt thereof.Type: GrantFiled: November 1, 2018Date of Patent: October 20, 2020Assignee: Taiho Pharmaceutical Co., Ltd.Inventors: Isao Miyazaki, Tadashi Shimamura, Masanori Kato, Hidenori Fujita, Satoru Iguchi
-
Patent number: 10809237Abstract: The present invention provides a novel method that is capable of detecting a trifluridine-related substance from a sample containing trifluridine or a salt thereof by high-performance liquid chromatography comprising two steps that are performed under gradient conditions. More specifically, the method is for detecting a trifluridine-related substance, the method comprising the step of subjecting a sample containing trifluridine or a salt thereof to high-performance liquid chromatography using a mobile phase composed of an organic phase and an aqueous phase, wherein the step of high-performance liquid chromatography comprises steps 1 and 2 that satisfy the following requirements: Step 1: the percentage of the organic phase in the entire mobile phase is 1 to 14% by volume; and Step 2: after step 1, elution is performed by applying a gradient of increasing the percentage of the organic phase in the entire mobile phase.Type: GrantFiled: June 17, 2019Date of Patent: October 20, 2020Assignee: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Daisuke Takeda, Akiyo Kojima
-
Patent number: 10787457Abstract: The present invention provides a novel RET inhibitor comprising, as an active ingredient, a compound or a salt thereof that have not been known for their RET inhibitory activity, and also provides an agent for preventing or treating diseases (e.g., malignant tumors) that can be prevented or treated by RET inhibitory activity. The RET inhibitor comprises, as an active ingredient, a compound represented by Formula (I) below or a salts thereof: wherein A, R1 to R3, X, and n are as defined in the specification.Type: GrantFiled: November 29, 2018Date of Patent: September 29, 2020Assignee: Taiho Pharmaceutical Co., Ltd.Inventors: Isao Miyazaki, Tadashi Shimamura, Masanori Kato, Hidenori Fujita
-
Publication number: 20200297716Abstract: Provided are a therapeutic agent and a pharmaceutical composition exerting an excellent prophylactic or therapeutic effect on fibrosis and symptoms associated with fibrosis. The therapeutic agent for fibrosis comprises 4-[2-fluoro-4-[[[(2-phenylacetyl)amino]thioxomethyl]amino]-phenoxy]-7-methoxy-N-methyl-6-quinolinecarboxamide or a salt thereof as an active ingredient.Type: ApplicationFiled: June 2, 2020Publication date: September 24, 2020Applicant: TAIHO PHARMACEUTICAL CO., LTD.Inventor: Akio FUJIOKA
-
Publication number: 20200289411Abstract: The present invention provides an FTD and TPI-containing oral pharmaceutical composition which can be orally administered and is stable even under high humidity conditions. An oral pharmaceutical composition comprising ?,?,?-trifluorothymidine and 5-chloro-6-(2-iminopyrrolidine-1-yl) methyl-2, 4(1H, 3H)-pyrimidine dione hydrochloride as an active ingredient; and being substantially free of an additive comprising a metal salt.Type: ApplicationFiled: June 1, 2020Publication date: September 17, 2020Applicant: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Yoshito OHNISHI, Tetsuo OGATA
-
Publication number: 20200281904Abstract: To provide a prophylactic and/or therapeutic agent for diseases involving IDO expression, and a pharmaceutical composition for treating IDO-positive tumors. A prophylactic and/or therapeutic agent for diseases involving IDO expression, comprising an HSP90-inhibiting compound as an active ingredient; and a pharmaceutical composition for treating IDO-positive tumors.Type: ApplicationFiled: September 14, 2018Publication date: September 10, 2020Applicant: TAIHO PHARMACEUTICAL CO., LTD.Inventor: Hiromi MURAOKA
-
Publication number: 20200281927Abstract: It is intended to provide a novel method for treating a cancer using an FGFR inhibitor that exhibits a remarkably excellent antitumor effect and has fewer side effects. The present invention provides a combination preparation for the treatment of a malignant tumor comprising a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof, and one or more additional compound(s) having an antitumor effect or pharmaceutically acceptable salt(s) thereof, and a pharmaceutical composition comprising both the active ingredients. The present invention also provides an antitumor effect enhancer, an antitumor agent, a kit for malignant tumor treatment, etc. comprising a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: March 3, 2017Publication date: September 10, 2020Applicant: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Akihiro MIURA, Hiroshi SOOTOME
-
Publication number: 20200276171Abstract: Provided is a novel method for treating cancer using an HSP90 inhibitor which exhibits a markedly superior antitumor effect and has a reduced side effect. An antitumor agent is characterized in that an azabicyclo compound of the following Formula (1) or a salt thereof is administered in combination with other antitumor agent(s).Type: ApplicationFiled: May 19, 2020Publication date: September 3, 2020Applicant: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Hiromi Muraoka, Akira Kanoh
-
Publication number: 20200270260Abstract: The present invention provides a novel RET inhibitor comprising, as an active ingredient, a compound or a salt thereof that have not been known for their RET inhibitory activity, and also provides an agent for preventing or treating diseases (e.g., malignant tumors) that can be prevented or treated by RET inhibitory activity. The RET inhibitor comprises, as an active ingredient, a compound represented by Formula (I) below or a salts thereof: wherein A, R1 to R3, X, and n are as defined in the specification.Type: ApplicationFiled: April 22, 2020Publication date: August 27, 2020Applicant: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Isao MIYAZAKI, Tadashi SHIMAMURA, Masanori KATO, Hidenori FUJITA
-
Publication number: 20200270261Abstract: The present invention provides a novel RET inhibitor comprising, as an active ingredient, a compound or a salt thereof that have not been known for their RET inhibitory activity, and also provides an agent for preventing or treating diseases (e.g., malignant tumors) that can be prevented or treated by RET inhibitory activity. The RET inhibitor comprises, as an active ingredient, a compound represented by Formula (I) below or a salts thereof: wherein A, R1 to R3, X, and n are as defined in the specification.Type: ApplicationFiled: April 22, 2020Publication date: August 27, 2020Applicant: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Isao MIYAZAKI, Tadashi SHIMAMURA, Masanori KATO, Hidenori FUJITA